[1] Angus DC, van der Poll T. Severe sepsis and septic shock [J]. N Engl J Med, 2013, 369(9): 840-851. [2] Adib-Conquy M, Cavaillon JM. Host inflammatory and anti-inflammatory response during sepsis [J]. Pathol Biol, 2012, 60(5): 306-313. [3] Otto GP, Sossdorf M, Claus RA, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate [J]. Crit Care, 2011, 15(4): 183-191. [4] Fan H, Cook JA. Molecular mechanisms of endotoxin tolerance [J]. J Endotoxin Res, 2004, 10(2): 71-84. [5] 孙瑞明, 杨光田. 内毒素耐受对脓毒症大鼠肠道功能保护作用的实验研究[D]. 武汉: 华中科技大学,2008. [6] 周苏明, 吴文溪. 细菌脂蛋白耐受对炎症反应信号转导通路的影响以及对脓毒症小鼠心功能的保护作用[D]. 南京: 南京医科大学, 2007. [7] 张静, 瞿介明, 潘珏, 等. 内毒素耐受大鼠与正常大鼠急性肺损伤反应比较[J]. 中国呼吸与危重监护杂志, 2003, 2(6): 346-350. [8] Bin Li, Rong Zhang, Jun Li, et al. Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-κB activation [J]. Int Immunopharmacol, 2008, 8(3): 379-389. [9] Angus DC. The search for effective therapy for sepsis: back to the drawing board [J]? JAMA, 2011, 306(23): 2614-2615. [10]Cohen J, Opal S, Calandra T. Sepsis studies need new direction [J]. Lancet Infect Dis, 2012, 12(7): 503-505. [11]Opal SM, LaRosa SP. Recombinant human activated protein C as a therapy for severe sepsis: lessons learned[J]? Am J Respir Crit Care Med, 2013, 187(10): 1041-1043. [12]Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach [J]. Lancet Infect Dis, 2013, 13(3): 260-268. [13]Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock [J]. Clin Infect Dis, 2002, 34(8): 1084-1093. [14]Hutchins NA, Unsinger J, Hotchkiss RS, et al. The new normal: immunomodulatory agents against sepsis immune suppression [J]. Trends Mol Med, 2014, 20(4): 224-233. |